Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Vaccine Technology 2009 Conference

Veterinary Diagnostics Markets

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

Royalty Financing Agreements in Pharma, Biotech and Diagnostics

New Products

Attention Deficit Hyperactivity Disorder: Diagnosis and Treatment

Bioinformatics Market Potential

Biotechnology in the European Union; Trends, Investing & Country Profiles

China Pharmaceutical Industry: Analysis and Market Trends

European Generic Drug Market Potential

Global Biotechnology Markets Trends

Strategic Alliances in World Pharma and Biotech Markets

Understanding China's Chemical Industry

Understanding Genomics and Global Health Impacts

Understanding Pharmacogenomics

BioPortfolio | VennBio Reports

Hypertension: Treatments and Prescribing Practices - A Global Survey
This report presents the findings of a global survey on current treatments and prescribing practices for Hypertension. These findings were made following the participation of more than 280 clinics worldwide, which provided detailed information of their treatment practices.

Today, approximately 1 billion people worldwide have high blood pressure, a figure expected to increase to 1.5 billion by 2025, affecting 1 in 3 adults over the age of 20 (Lancet. 2005;365:217-223). Hypertension is commonly seen in developing as well as developed countries and, where it remains untreated, presents a major risk factor for heart attack, stroke, kidney failure and other cardiovascular diseases.

Stroke: Treatments and Prescribing Practices - A Global Survey 2009
A global survey of current treatments and prescribing practices for Ischaemic Stroke, Haemorrhagic Stroke and Transient Ischaemic Attack (TIA)

Focused on drug-based treatments, this report presents the findings of a comprehensive survey, from information provided by more than 230 clinics worldwide

In-depth feedback on Stroke treatment needs and limitations, from the clinician’s perspective

Global data relevant to treatment practices, markets and opportunities

This study was conducted by Biopharm Reports, between March and September 2009

Neuropathic Pain: Treatments and Prescribing Practices - A Global Survey 2009
This report presents the findings of a global survey on current therapeutic approaches to the treatment of Neuropathic Pain (NP). These findings were made following the participation of more than 330 physicians, who provided details of their treatments and prescribing practices.

Alzheimer's Disease Biomarkers, 2009
This report gives a comprehensive and up-to-date review of Alzheimer's disease (AD) biomarkers. Recent years have seen significant advances in this field. Whilst considerable effort has focused on A? and tau related markers, a substantial number of other molecules have been identified and studied, that may offer new opportunities.

Cancer Drug Resistance
Drug resistance is the single most important cause of cancer treatment failure and carries a massive burden to patients, healthcare providers, drug developers and society. It is estimated that Multidrug Resistance (MDR) plays a major role in up to 50% of cancer cases. Today, most drug therapies involve multiple agents, as it is almost universally the case that single drugs (or single-target drugs) will encounter resistance.

Peripheral Neuropathy and Neuropathic Pain, 2008
Current, pipeline and emerging drugs for the treatment of peripheral neuropathy and neuropathic pain

This report estimates that Peripheral Neuropathy (PN) and Neuropathic Pain (NP) affect 170 to 270 million individuals globally. PN and NP are causally linked to a number of diseases, however diabetes, cancer and HIV alone are expected to increase the prevalence of PN and NP by more than 10% by 2012. PN and NP are areas of significant and critical unmet need. There are no cures for PN and NP is difficult to treat and often unresponsive to all available therapies. Today's armoury of drugs for the treatment of NP shows significant reliance on "second-indication" drugs, which were initially developed to treat other primary indications (e.g. anticonvulsants, antidepressants). This report gives a comprehensive update on all current drugs, together with the entire drug development pipeline, from pre-clinical through to Phase III, Registration and initial Launch. The pipeline includes 80 candidates being developed to treat PN and NP as a primary indication and 60 "second-indication" drugs. More than 300 patents published in the PN and NP field between 2002 and 2007 have also been assessed and presented, together with the identification of potential candidate molecules and drug targets which have not entered the development pipeline, but which may do so in the future. This report was written to provide a comprehensive update on therapeutic developments relating to PN and NP, both in tackling its most serious and debilitating symptoms, but also in targeting and potentially correcting the underlying disease mechanisms. Commercial evaluation and assessments including markets, market size, market sectors, sales and trends relating to PN and NP are also included in this report.

Antibiotics and Drug Resistance 2008
New drug innovation and the strategy to combat antibiotic resistance mechanisms

This report reviews new drug innovation and strategy to combat antibiotic resistance mechanisms. This embraces current research-stage activities, patents published in the last five years, the entire pharmaceutical development pipeline and today's existing armoury of anti-bacterial drugs. The report reviews 370+ pipeline antibiotics and anti-bacterial technologies (from pre-clinical to Phase III/initial launch), 340+ antibiotic patents published between Jan 2002 and May 2007 and more than 200 fully launched antibiotics. It identifies and discusses new antibiotics, technologies and strategies at the anti-bacterial mechanistic level, that are specifically being developed to combat resistance mechanisms. The opportunities which they potentially offer in tackling the increasing global threat of antibiotic resistance, are discussed.

Cancer Stem Cells Emerging Therapeutic Diagnostic and Market Opportunities
Overview: Tumours and haematological cancers contain small populations of cells that are believed to play a critical role in the progression of the disease. These cells, named Cancer Stem Cells (CSCs), have been found in leukaemia, myeloma, breast, prostate, pancreas, colon, brain and lung cancers. It is thought that CSCs are critically involved in the development and metastatic spread of cancer. CSCs have also demonstrated resistance to a number of conventional therapies and it is thought that that this explains why it is difficult to completely eradicate the disease and why recurrence is an ever-present threat. If these findings are now confirmed in the clinic, the selective targeting of CSCs will offer a new paradigm in both cancer therapeutics and diagnostics.

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions